<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699890</url>
  </required_header>
  <id_info>
    <org_study_id>UF7733</org_study_id>
    <nct_id>NCT04699890</nct_id>
  </id_info>
  <brief_title>Development of Specific Diagnostic Tools for Cardiac Insufficiency With Preserved Ejection Fraction</brief_title>
  <acronym>MeDIAGSTOLE</acronym>
  <official_title>Development of Specific Diagnostic Tools for Cardiac Insufficiency With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MeDIAGSTOLE project aims to develop diagnostic tools for heart failure with preserved&#xD;
      ejection fraction (IC / FEp), a pathology that is difficult to diagnose and to manage&#xD;
      clinically in the absence of targeted treatment . The IC / FEp concerns the elderly&#xD;
      population with comorbidities such as hypertension, obesity, anemia and atrial fibrillation.&#xD;
      In the absence of specific biomarkers, clinical diagnosis is based on serum markers of heart&#xD;
      failure with reduced ejection fraction (IC / FEr). The identification of new biomarkers,&#xD;
      genetic and / or cellular, specific for IC / FEp would be an important innovation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>diagnostic power of a multi-marker approach (progenitor cells)</measure>
    <time_frame>At 12 months</time_frame>
    <description>to estimate the diagnostic power of a the multi-marker approach combining 5 circulating biomarkers (biochemical and cellular) in IC / FEp versus heart failure with reduced ejection fraction (IC / FEr) : first biomarker (cellular) : progenitor cells Value in µL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>diagnostic power of a multi-marker approach (monocytes)</measure>
    <time_frame>At 12 months</time_frame>
    <description>to estimate the diagnostic power of a the multi-marker approach combining 5 circulating biomarkers (biochemical and cellular) in IC / FEp versus heart failure with reduced ejection fraction (IC / FEr) : second biomarker (cellular) : monocytes Value in µL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>diagnostic power of a multi-marker approach (NT-proBNP)</measure>
    <time_frame>At 12 months</time_frame>
    <description>to estimate the diagnostic power of a the multi-marker approach combining 5 circulating biomarkers (biochemical and cellular) in IC / FEp versus heart failure with reduced ejection fraction (IC / FEr) : third biomarker (biochemical) : NT-proBNP Value in ng/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>diagnostic power of a multi-marker approach (sST2)</measure>
    <time_frame>At 12 months</time_frame>
    <description>to estimate the diagnostic power of a the multi-marker approach combining 5 circulating biomarkers (biochemical and cellular) in IC / FEp versus heart failure with reduced ejection fraction (IC / FEr) : fourth biomarker (biochemical) : sST2 Value in ng/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>diagnostic power of a multi-marker approach (PIIINP)</measure>
    <time_frame>At 12 months</time_frame>
    <description>to estimate the diagnostic power of a the multi-marker approach combining 5 circulating biomarkers (biochemical and cellular) in IC / FEp versus heart failure with reduced ejection fraction (IC / FEr) : fifth biomarker (biochemical) : PIIINP Value in ng/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation in gene expression</measure>
    <time_frame>At 12 months</time_frame>
    <description>Carry out a molecular approach based on high throughput genetic sequencing. This will make it possible to determine the variations in gene expression : coding or not coding RNA.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>preserved ejection fraction</arm_group_label>
    <description>Patients with a preserved ejection fraction (HF / FEp)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>reduced ejection fraction</arm_group_label>
    <description>Patients with a reduced ejection fraction (HF / FEr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without heart failure</arm_group_label>
    <description>Patient without heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling, questionnaires and specific exams</intervention_name>
    <description>Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.</description>
    <arm_group_label>preserved ejection fraction</arm_group_label>
    <arm_group_label>reduced ejection fraction</arm_group_label>
    <arm_group_label>without heart failure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The inclusions will be done in the Cardiology department (Prof. F. Roubille) by the team of&#xD;
        cardiologists trained in the study. Patients eligible for the study will be selected either&#xD;
        from already hospitalized patients or from outside patients during the weekly consultation.&#xD;
&#xD;
        In order to be representative of the population of interest (patients followed in&#xD;
        cardiology consultation) and to limit inclusion bias, the inclusions will be exhaustive and&#xD;
        consecutive. A collection of reasons for refusal will be made for the construction of the&#xD;
        study flow chart.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria group 1 (ejection fraction ≥ 50%) :&#xD;
&#xD;
          -  Age &gt; or = 65,&#xD;
&#xD;
          -  heart failure (NT-proBNP ≥ 450 pg/mL during hospitalization or follow-up)&#xD;
&#xD;
          -  echocardiography showing an ejection fraction ≥ 50%,&#xD;
&#xD;
          -  patients already hospitalized and followed in cardiology consultation,&#xD;
&#xD;
          -  patients agreeing to sign informed consent,&#xD;
&#xD;
          -  patient affiliated to french health care system.&#xD;
&#xD;
        Inclusion Criteria group 2 (ejection fraction &lt; 50%) :&#xD;
&#xD;
          -  Age &gt; or = 65,&#xD;
&#xD;
          -  heart failure (NT-proBNP ≥ 450 pg/mL during hospitalization or follow-up)&#xD;
&#xD;
          -  echocardiography showing an ejection fraction &lt; 50%,&#xD;
&#xD;
          -  patients already hospitalized and followed in cardiology consultation,&#xD;
&#xD;
          -  patients agreeing to sign informed consent,&#xD;
&#xD;
          -  patient affiliated to french health care system.&#xD;
&#xD;
        Inclusion Criteria group 3 (without heart failure) :&#xD;
&#xD;
          -  Age &gt; or = 65,&#xD;
&#xD;
          -  patients already hospitalized and followed in cardiology consultation for one of the&#xD;
             following pathology : stable coronaropathy without heart failure, arterial&#xD;
             hypertension without heart failure, auricular fibrilation without heart failure&#xD;
&#xD;
          -  patients agreeing to sign informed consent,&#xD;
&#xD;
          -  patient affiliated to french health care system.&#xD;
&#xD;
        Exclusion Criteria for all groups:&#xD;
&#xD;
          -  Hemodynamic instability (cardiogenic shock),&#xD;
&#xD;
          -  any condition leading to a prognosis of less than 7 days,&#xD;
&#xD;
          -  Known hepatocellular insufficiency, or known hepatic cirrhosis&#xD;
&#xD;
          -  ASAT / ALAT&gt; 10N excluding cardiac cause&#xD;
&#xD;
          -  Any conditions that may put the patient at risk or increase the risk of non-compliance&#xD;
             with the protocol or lost to follow-up according to the opinion of the investigator&#xD;
&#xD;
          -  Patient under legal protection, under guardianship or under curatorship&#xD;
&#xD;
          -  Inability to give the subject informed information&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvain Aguilhon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvain Aguilhon, MD</last_name>
    <phone>+33788014858</phone>
    <email>s-aguilhon@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvain Aguilhon</last_name>
    </contact>
    <investigator>
      <last_name>Sylvain Aguilhon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure (HF)</keyword>
  <keyword>progenitors cells</keyword>
  <keyword>biomarkers</keyword>
  <keyword>diastolic dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

